Disease relevance of Rpl13a

• It turned out that all membrane fractions from a variety of T lineage cells (mutant EL4, parent EL4, BW5147, P198 thymomas, normal T cells) and B lineage cells (BCL1 lymphoma, X63Ag8 cytoplasma, normal B cells) exhibited similar B cell stimulating activity in both assays [1].
• The P815 and P198 cell lines are clonally related mouse mastocytoma cell lines [2].

High impact information on Rpl13a

• Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide [3].
• As observed with gene P91A, we found that a fragment of gene P198 that contained only exons 3-7, cloned in nonexpression vectors, transferred efficiently the expression of the antigen [3].
• We conclude that tum- mutation P198 generates a new epitope recognized by syngeneic T cells [3].
• By transfecting P815 cell line P1.HTR with DNA of tum- variant P198, we obtained transfectants expressing tum- antigen P198 that could be identified on the basis of their ability to stimulate anti-P198 CTL [3].
• This was repeated with DNA of a cosmid library derived from variant P198, and a cosmid carrying the sequence encoding antigen P198 was recovered from a transfectant [3].

Biological context of Rpl13a

• Structural comparison of these genes, including previously reported mouse Rpl13a, revealed a significant conservation of sequences in the promoter regions [4].
• A third, P198, was found to map to chromosome 7 and to be a member of a small gene family with other members on chromosomes 13, 14, and 15 [5].
• Multiple P198-related sequences were found in other mammalian species suggesting the P198 related gene family is a general feature of mammalian genomes [5].

Anatomical context of Rpl13a

• P198p is a ribosomal constituent, or a factor firmly linked to both the free and membrane-bound ribosomes [6].
• They differ in their biologic behavior in that P815 is a progressive tumor cell line, whereas P198 is a regressive one [2].
• On the other hand, P198 tumor cells expressed CD11b and CD80, which favor the recruitment of lymphocytes and antigen-presenting cells (APCs), as well as the elicitation of antitumor immunity [2].

Analytical, diagnostic and therapeutic context of Rpl13a

• While two immunizations with peptide P198 in SBAS-1c adjuvant induced measurable CTL responses in less than 10% of DBA/2 mice, the addition of IL-12 to the peptide adjuvant mixture resulted in high CTL responses in nearly all mice [7].

References